Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-11-28
2006-11-28
Russel, Jeffrey Edwin (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C424S085100, C514S012200, C514S021800
Reexamination Certificate
active
07141544
ABSTRACT:
The present invention relates to stable pharmaceutical protein formulations that are stabilized using peptide stabilizers selected from the group consisting of Gly-Gly, Gly-Gly-Gly, Gly-Tyr, Gly-Phe, Gly-His, Gly-Asp, Gly-Ala, Ala-Gly, Ala-Ala, derivatives thereof and mixtures thereof. Furthermore, the present invention relates to stable pharmaceutical formulations comprising erythropoietin and peptide stabilizers selected from dipeptides, tripeptides, tetrapeptides, pentapeptides, and mixtures thereof. In addition to peptide stabilizers, the formulations may contain surfactants.
REFERENCES:
patent: 4703008 (1987-10-01), Lin
patent: 4992419 (1991-02-01), Woog et al.
patent: 5141905 (1992-08-01), Rosen et al.
patent: 5366875 (1994-11-01), Wozney et al.
patent: 5597897 (1997-01-01), Ron et al.
patent: 5661125 (1997-08-01), Strickland
patent: 5688679 (1997-11-01), Powell
patent: 5705482 (1998-01-01), Christensen et al.
patent: 5919757 (1999-07-01), Michaelis et al.
patent: 6277367 (2001-08-01), Yamazaki et al.
patent: 6306432 (2001-10-01), Shirley et al.
patent: 6328728 (2001-12-01), Holladay et al.
patent: 6538028 (2003-03-01), Pierson et al.
patent: 6605699 (2003-08-01), Ni et al.
patent: 6624289 (2003-09-01), Bajaj
patent: 2002/0055582 (2002-05-01), Murakami et al.
patent: 2002/0058608 (2002-05-01), Cormier et al.
patent: 2003/0092622 (2003-05-01), Sato et al.
patent: 2003/0162711 (2003-08-01), Bjorn et al.
patent: 2004/0166572 (2004-08-01), Wan et al.
patent: 2005/0288222 (2005-12-01), Hayward et al.
patent: 0 909 564 (1999-04-01), None
patent: WO 00/61169 (2000-10-01), None
patent: WO 01/24814 (2001-04-01), None
patent: WO 01/60420 (2001-08-01), None
patent: WO 01/64241 (2001-09-01), None
patent: WO 02/14356 (2002-02-01), None
patent: WO 02/014356 (2002-02-01), None
patent: WO 03/020299 (2003-03-01), None
Webster's II New Riverside University Dictionary. Boston: Houghton Mifflin Company.1984, p. 854.
Dugas, H., et al., “Chemical Synthesis of Proteins,” Bioorganic Chemistry of the Amino Acids, 1981, pp. 54-92, Springer-Verlag, New York.
Harris, S., et al., “Effects of Transforming Growth Factor β on Bone Nodule Formation and Expression of Bone Morphogenetic Protein 2, Osteocalcin, Osteopontin, Alkaline Phosphatase, and Type I Collagen mRNA in Long-Term Cultures of Fetal Rat Calvarial Osteoblasts,” Journal of Bone and Mineral Research, 1994, pp. 855-863, vol. 9, No. 6, Mary Ann Liebert, Inc.
Nimtz, et al., “Structures of Sialylated Oligosaccharides of Human Erythropoietin Expressed In Recombinant BHK-21 Cells,” Eur. J. Biochem., 1993, pp. 39-56, vol. 213.
Storring, P., et al., “Epoetin Alfa and Beta Differ in Their Erythropoietin Isoform Compositions and Biological Properties,” British Journal of Haematology, 1998, pp. 79-89, vol. 100.
Sytkowski, A., et al., “Biological Activity and Structural Stability of N-Deglycosylated Recombinant Human Erythropoietin,” Biochemical and Biophysical Research Communications, 1991, pp. 698-704, vol. 176, No. 2.
Tsuda, E., et al., “The Role of Carbohydrate in Recombinant Human Erythropoietin,” Eur. J. Biochem., 1990, pp. 405-411, vol. 188.
Urist, M., “Bone: Formation by Autoinduction,” Science, 1965, pp. 893-899, vol. 150.
Wozney, J., et al., “Novel Regulators of Bone Formation: Molecular Clones and Activities,” Science, 1988, pp. 1528-1534, vol. 242.
Morlock, Michael, et al., “Erythropoietin Loaded Microspheres Prepared from Biodegradable LPLG-PEO-LPLG Triblock Copolymers: Protein Stabilization and In-Vitro Release Properties”, Journal of Controlled Release 56, pp. 105-115 (1998).
International Search Report, PCT/US2004/031094, from the International Searching Authority dated Jan. 18, 2005.
Faict Dirk
Somers Fabian
Baxter Healthcare S.A.
Baxter International Inc.
Russel Jeffrey Edwin
Senniger Powers
LandOfFree
Stabilization of pharmaceutical protein formulations with... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Stabilization of pharmaceutical protein formulations with..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Stabilization of pharmaceutical protein formulations with... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3676912